SOHM, Inc. Announces Allowance of Another Divisional Patent in the Republic of South Korea
SOHM Inc. (OTCID:SHMN) has secured a new patent allowance in South Korea for its innovative gene-editing technology. The patent covers the company's ABBIE gene-editing platform, which combines dCas9 with retroviral integrases for targeted DNA sequence incorporation.
The approved technology, titled "CAS9 Retroviral Integrase and CAS9 Recombinase Systems," strengthens SOHM's global intellectual property portfolio, following previous successes in Europe. This advancement is particularly significant for developing next-generation allogeneic CAR-T therapies and regenerative medicine applications.
SOHM Inc. (OTCID:SHMN) ha ottenuto una nuova concessione di brevetto in Corea del Sud per la sua innovativa tecnologia di editing genetico. Il brevetto riguarda la piattaforma di editing genetico ABBIE, che combina dCas9 con integrasi retrovirali per l'integrazione mirata di sequenze DNA.
La tecnologia approvata, intitolata "Cas9 Retroviral Integrase and Cas9 Recombinase Systems", rafforza il portafoglio di proprietà intellettuale globale di SOHM, in seguito ai successi precedenti in Europa. Questo progresso è particolarmente significativo per lo sviluppo di terapie CAR-T allogeneiche di prossima generazione e per applicazioni di medicina rigenerativa.
SOHM Inc. (OTCID:SHMN) ha obtenido una nueva concesión de patente en Corea del Sur para su innovadora tecnología de edición genética. La patente cubre la plataforma de edición genética ABBIE, que combina dCas9 con integrasas retróvirales para la incorporación dirigida de secuencias de ADN.
La tecnología aprobada, titulada "CAS9 Retroviral Integrase and CAS9 Recombinase Systems", fortalece el portafolio global de propiedad intelectual de SOHM, tras los éxitos previos en Europa. Este avance es particularmente significativo para el desarrollo de terapias CAR-T alogénicas de próxima generación y para aplicaciones de medicina regenerativa.
SOHM Inc. (OTCID:SHMN)이(가) 유럽에서의 성공에 이어, 혁신적인 유전자 편집 기술에 대해 한국에서 새로운 특허 허가를 획득했습니다. 이 특허는 회사를 둘러싼 ABBIE 유전자 편집 플랫폼을 커버하며, dCas9과 레트로바이러스 연관효소를 결합해 특정 DNA 서열의 삽입을 가능하게 합니다.
승인된 기술은 "CAS9 Retroviral Integrase and CAS9 Recombinase Systems"로 명명되었으며, SOHM의 글로벌 지적재산 포트폴리오를 강화합니다. 이 진전은 차세대 동종 CAR-T 치료제 개발과 재생의학 응용에 특히 중요합니다.
SOHM Inc. (OTCID:SHMN) a obtenu une nouvelle allowance de brevet en Corée du Sud pour sa technologie d’édition génétique innovante. Le brevet couvre la plateforme d’édition génétique ABBIE, qui combine dCas9 avec des intégrases rétrovirales pour l’intégration ciblée de séquences d’ADN.
La technologie approuvée, intitulée « CAS9 Retroviral Integrase and CAS9 Recombinase Systems », renforce le portefeuille mondial de propriété intellectuelle de SOHM, après des succès antérieurs en Europe. Cette avancée est particulièrement significative pour le développement de thérapies CAR-T allogéniques de nouvelle génération et pour les applications de médecine régénérative.
SOHM Inc. (OTCID:SHMN) hat in Südkorea eine neue Patentanmeldung für seine innovative Gen-Editierungstechnologie erhalten. Das Patent deckt die ABBIE-Gen-Editierungsplattform ab, die dCas9 mit retroviralen Integrasen kombiniert, um gezielt DNA-Sequenzen zu integrieren.
Die genehmigte Technologie mit dem Titel "CAS9 Retroviral Integrase and CAS9 Recombinase Systems" stärkt SOHMs globales Portfolio an geistigem Eigentum, nach bisherigen Erfolgen in Europa. Diese Entwicklung ist besonders bedeutend für die Entwicklung von Next-Generation allogene CAR-T-Therapien und Anwendungen in der regenerativen Medizin.
SOHM Inc. (OTCID:SHMN) حصلت على إذن patent جديد في كوريا الجنوبية لتقنيتها المبتكرة في تعديل الجينات. يغطي patent منصة ABBIE لتعديل الجينات، التي تجمع بين dCas9 وإنزيمات اندماج Retrovirales لإدماج تسلسلات DNA المستهدفة.
التقنية المعتمدة، المعنونة "CAS9 Retroviral Integrase and CAS9 Recombinase Systems"، تقوّي محفظة الملكية الفكرية العالمية لـ SOHM، بعد النجاحات السابقة في أوروبا. هذا التقدم ذو أهمية خاصة لتطوير علاجات CAR-T جميعية من الجيل القادم وتطبيقات في طب Regenerative.
SOHM Inc.（OTCID：SHMN） 已在韩国获得一项新的专利授权，针对其创新的基因编辑技术。该专利涵盖公司的ABBIE 基因编辑平台，该平台将 dCas9 与反转录病毒整合酶结合，实现定向DNA序列的插入。
获批的技术，题为《CAS9 Retroviral Integrase and CAS9 Recombinase Systems》，加强了SOHM在全球的知识产权组合，此前在欧洲已取得成功。这一进展对于开发
- Patent allowance in South Korea expands global IP portfolio
- Technology builds on previous successful patent approvals in Europe
- Platform shows potential for next-generation CAR-T therapies development
- None.
CHINO HILLS, CALIFORNIA / ACCESS Newswire / September 15, 2025 / SOHM, Inc. (OTCID:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, a leader in Gene Editing and Cell Engineering is pleased to announce that it has received a Notice of Allowance/Approval from the South Korea Patent Office for its innovative technology entitled - "CAS9 Retroviral Integrase and CAS9 Recombinase Systems for Targeted Incorporation of a DNA Sequence into a Genome of a Cell or Organism"
Patent Application No. 10-2024-7041475
This patent builds on our growing global IP portfolio around the ABBIE gene-editing platform, which fuses dCas9 with retroviral integrases. Dr. David Aguilar said.
Following earlier successes in Europe, this Korean allowance reinforces ABBIE's potential as a first-in-class solution for site-specific integration - a critical step toward developing next-generation allogeneic CAR-T therapies, regenerative medicine, and beyond.
At SOHM, we remain committed to building a global intellectual property estate that secures our innovations and drives partnerships worldwide.
For more information about SOHM Inc. and its groundbreaking work in biotechnology, please visit www.SOHM.com.
About SOHM, Inc.:
SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery.
For further information regarding this announcement or to explore potential collaborations, please contact:
SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: info@sohm.com
Phone: (714) 522-6700
Safe Harbor Statement:
This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.
SOURCE: SOHM, Inc.
View the original press release on ACCESS Newswire
FAQ
What patent did SOHM (SHMN) receive approval for in South Korea?
How does SOHM's ABBIE gene-editing platform work?
What markets has SOHM (SHMN) secured patent protection in for its gene-editing technology?
What are the potential applications of SOHM's patented gene-editing technology?
